PUBLICAÇÕES científicas

/cun/pt/investigacion/publicaciones-cientificas/areaMain/02
  • Functional Relationship between Leptin and Nitric Oxide in Metabolism

    Becerril S (1,2,3), Rodríguez A (4,5,6), Catalán V (7,8,9), Ramírez B (10,11,12), Unamuno X (13,14,15), Portincasa P (16), Gómez-Ambrosi J (17,18,19), Frühbeck G (20,21,22,23).

    (1) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (2) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (3) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (4) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (5) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (6) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (7) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (8) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (9) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (10) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (11) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (12) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (13) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (14) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (15) Medical Engineering Laboratory, University of Navarra, 31008 Pamplona, Spain.
    (16) Clinica Medica "A. Murri", Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Policlinico Hospital, 70124 Bari, Italy.
    (17) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (18) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (19) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (20) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (21) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (22) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (23) Department of Endocrinology & Nutrition, Clínica Universidad de Navarra, 31008 Pamplona, Spain.

    Nutrients 06 de SETEMBRO de 2019

  • Feasibility of transaortic approach to map an atrial re-entrant tachycardia within the pulmonary venous atrium in a patient with d-transposition of the great arteries after Mustard operation by using a high-density mini-basket catheter

    Solimene F (1), Maddaluno F (2), Schillaci V (1), García-Bolao I (3).

    (1)Department of Electrophysiology, Clinica Montevergine, Mercogliano, Italy.
    (2) Boston Scientific, Italy.
    (3) Department of Cardiology and Cardiac Surgery, Clínica Universidad de Navarra, Pamplona, Spain.

    Journal of Cardiovascular Electrophysiology 26 de AGOSTO de 2019

  • Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

    Ray-Coquard I (1), Cibula D (2), Mirza MR (3), Reuss A (4), Ricci C (5), Colombo N (6), Koch H (7), Goffin F (8), González-Martin A (9), Ottevanger PB 10, Baumann K (11), Bjørge L (12), Lesoin A (13), Burges A (14), Rosenberg P (15), Gropp-Meier M (16), Harrela M (17), Harter P (18), Frenel JS (19), Minarik T (20), Pisano C (21), Hasenburg A (22), Merger M (23), du Bois A (18); AGO Study Group-led GCIG/ENGOT Intergroup Consortium.

    (1) GINECO and Medical Oncology Department, Centre Léon Bérard, University Claude Bernard Lyon, Lyon, France.
    (2) AGO and Oncogynecologic Center, Department of Obstetrics and Gynecology, General Faculty Hospital, Charles University of Prague, Prague, Czech Republic.
    (3) NSGO and Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
    (4) AGO and Coordinating Center for Clinical Trials, Philipps-University of Marburg, Marburg, Germany.
    (5) MITO and Division of Gynecologic Oncology, Department of Women and Children's Health and Public Health, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
    (6) MaNGO and European Institute of Oncology and University of Milan Bicocca, Milan, Italy.
    (7) AGO Austria and Department of Obstetrics and Gynecology, Paracelsus Medical University, Salzburg, Austria.
    (8) BGOG and CHU de Liège, University of Liège, Liège, Belgium.
    (9) GEICO and Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain.
    (10) DGOG and Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.
    (11) AGO and Department of Gynecology, Klinikum der Stadt Ludwigshafen GmbH, Ludwigshafen, Germany.
    (12) NSGO and Department of Gynecology, Haukeland Universitetssykehus, Bergen, and Center for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.
    (13) GINECO and Department of Gynecologic Cancer and Medical Oncology, Centre Oscar Lambret, Lille, France.
    (14) AGO and Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Germany.
    (15) NSGO and Department of Oncology, University Hospital Linköping, Linköping, Sweden.
    (16) AGO and Department of Gynecology and Obstetrics, Oberschwabenklinik, Krankenhaus St. Elisabeth, Ravensburg, Germany.
    (17) NSGO and Department of Gynoncology and Gynecology and Obstetrics, Kymenlaakso Central Hospital, Kotka, Finland.
    (18) AGO and Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.
    (19)GINECO and Centre René Gauducheau, Institut de Cancerologie de l'Ouest, Saint Herblain, France.
    (20) NSGO and National Institute of Oncology, Bratislava, Slovakia.
    (21) MITO and Department of Uro-Gynecologic Oncology, Istituto Nazionale per Io Studio e la Cura dei Tumori 'Fondazione G. Pascale' IRCCS, Napoli, Italy.
    (22) AGO and Department of Obstetrics and Gynecology, University Medical Center, Mainz, Germany.
    (23) Oncology Medicine, Boehringer Ingelheim International GmbH, Biberach, Germany.

    International Journal of Cancer 05 de AGOSTO de 2019

  • Floppy Closing Door Epiglottis Treated Successfully with an Mhealth Application Based on Myofunctional Therapy

    O'Connor Reina C (1), Plaza Mayor G (2), Ignacio-Garcia JM (3), Baptista Jardin P (4), Garcia-Iriarte MT (5), Casado-Morente JC (1).

    (1) Chief of Department of Otorhinolaryngology, Hospital Quiron Salud Marbella, Hospital Quiron Salud Campo de Gibraltar, Cádiz, Spain.
    (2) Chief of Department of Otorhinolaryngology, Hospital Sanitas La Zarzuela, Hospital Universitario Fuenlabrada, Fuenlabrada, Spain.
    (3) Chief of Neumology Department, Hospital Quiron Salud Marbella, Hospital Quiron Salud Campo de Gibraltar, Cádiz, Spain.
    (4) Otorhinolaryngology Department, Clinica Universitaria de Navarra, Navarra, Spain.
    (5) Otorhinolaryngology Department, Hospital La Merced, Osuna, Sevilla, Spain.

    Case Reports in Otolaryngology 01 de JULHO de 2019

  • Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

    Puig N (1), Paiva B (2), Lasa M (3), Burgos L (3), Perez JJ (1), Merino J (3), Moreno C (3), Vidriales MB (1), Toboso DG (1), Cedena MT (4), Ocio EM (1), Lecumberri R (3), García de Coca A (5), Labrador J (6), Gonzalez ME (7), Palomera L (8), Gironella M (9), Cabañas V (10), Casanova M (11), Oriol A (12), Krsnik I (13), Pérez-Montaña A (14), de la Rubia J1 (5), de la Puerta JE (16), de Arriba F (17), Prosper F (3), Martinez-Lopez J (4), Lecrevisse Q (18), Verde J (19), Mateos MV (3), Lahuerta JJ (4), Orfao A (18), San Miguel JF (3).

    (1) Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain.
    (2) Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBERONC Pamplona, Pamplona, Spain.
    (3) Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBERONC Pamplona, Pamplona, Spain.
    (4) Hospital 12 de Octubre, Madrid, CNIO, Universidad Complutese CIBERONC, Madrid, Spain.
    (5) Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
    (6) Hospital Universitario de Burgos, Burgos, Spain.
    (7) Hospital de Cabueñes, Gijon, Spain.
    (8) Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain.
    (9) Hospital Universitari Vall d'Hebron, Barcelona, Spain.
    (10) Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
    (11) Hospital Costa del Sol, Marbella, Spain.
    (12) Institut Català d'Oncologia i Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain.
    (13) Hospital Puerta de Hierro, Madrid, Spain.
    (14) Hospital Son Espases, Palma, Spain.
    (15) Hospital Doctor Peset, Valencia, Spain.
    (16) Hospital de Galdakao, Vizcaya, Spain.
    (17) Hospital Universitario Morales Meseguer. IMIB-Arrixaca, Murcia, Spain.
    (18) Servicio General de Citometría, Universidad de Salamanca, IBSAL, and IBMCC CSIC-USAL, CIBERONC, Salamanca, Spain.
    (19) Cytognos SL, Salamanca, Spain.

    Leukemia 01 de MAIO de 2019

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra